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Abstract An 87-year-old woman developed abdominal
wall hematoma and upper gastrointestinal bleeding during
treatment with cefoperazone/sulbactam for pneumonia. The
woman received cefoperazone/sulbactam at 4.5 g twice
daily for intravenous infusion. After 7 days, she developed
sudden onset of left lower abdominal pain, associated with
subcutaneous mass, and vomited a coffee-colored liquid.
Investigations revealed a coagulation index abnormality and
activated partial thromboplastin time and prothrombin time
increased obviously. She was diagnosed with cefoperazone-
induced hemorrhage. Cefoperazone/sulbactam was discon-
tinued and the patient received vitamin K1. The blood
coagulation function improved and hematoma disappeared
after 3 days. A Naranjo assessment score of 6 was obtained,
indicating a probable relationship between the patient’s
coagulation function disorder and her use of the suspect drug.
Key Points
Cefoperazone/sulbactam might induce abdominal
wall hematoma.
Clinicians should be aware of the side effect even
though it is very rare.
The mechanism of abnormal coagulation induced by
cefoperazone is still unclear.
Introduction
The third-generation cephalosporin antibiotic cefoperazone
has been widely used since the 1980s [1, 2]. Cefopera-
zone/sulbactam (Sulperazon; Pfizer Inc., China) is an
antimicrobial combination including sulbactam, which can
enhance the activity of enzyme-resistant antibiotics. Cefop-
erazone/sulbactam as a broad-spectrum antibiotic is used in
cases of moderate to severe infection [3–7]. A great deal of
information has accumulated regarding its possible adverse
effects, including hypersensitivity vasculitis and hypona-
tremia [1, 8–10]. One important side effect is vitamin K
deficiency, which can induce abnormal coagulation function
and hemorrhage [11, 12]. Fortunately, this is treatable with
vitamin K supplementation [13]. Over the years, this effect
has fallen out of general notice because the incidence is so
low. About 30 articles mentioning cefoperazone-induced
hypoprothrombinemia and hemorrhage have been entered
into PubMed ever. The most frequent site of bleeding was
the urinary tract, and more than three-quarters of cases of
bleeding from this area were microscopic. The second most
frequent site was the integument, then bleeding from the
nose, mouth, or pharynx, then the digestive system [14]. No
cases of subcutaneous hematoma have been reported. Here,
a case of abdominal wall hematoma most likely induced by
cefoperazone/sulbactam is reported and cefoperazone-in-
duced hemorrhage is reviewed.
Case Report
The patient (female, 87 years old) was hospitalized on June
16, 2014, because of yellow purulent sputum and cough with
dyspnea lasting 5 days. The chest film suggested right lower
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lung infection and a small amount of pleural effusion on the
right side. She had a history of chronic renal insufficiency,
blood urea nitrogen was 16.1 mmol/L, and creatinine was
334 lmol/L at the time of admission. There was no bleeding
history. The pneumonia was successively treated with
mezlocillin and piperacillin/tazobactam, but symptoms did
not improve. The antibiotic was upgraded to cefopera-
zone/sulbactam 4.5 g twice daily intravenous infusion from
June 23. The symptoms improved daily. At 4:00, June 30, the
patient felt a sudden onset of left lower abdominal pain,
associated with subcutaneous mass. This mass was round,
6 9 6 cm in size, and hard to touch. The patient experienced
tenderness with no obvious wave motion. Abdominal com-
puted tomography (CT) showed possible hematoma at the
lower left abdominal wall (Fig. 1a). Abdominal B ultrasound
revealed mixed masses (100 9 36 mm, smooth border,
unhomogenous echo) at the left lower abdominal wall
(Fig. 1b). The patient had not defecated in the past 48 h, and
incarceration of a ventral hernia was considered. Fasting,
rehydration, spasmolysis, and acesodyne were implemented,
but these measures did not ease the symptoms. At 17:00, June
30, the patient vomited a coffee-colored liquid, about
200 mL. Occult bloods test of vomit were positive. On July
1, the patient’s condition had not improved, there was no anal
flatus or defecation, the abdomen was soft, and the mass still
had apparent tenderness. No skin ecchymosis was observed
nearby. The blood coagulation showed on July 1: pro-
thrombin time (PT) 80 s, partial thromboplastin time (PTT)
57.1 s, PT international normalized ratio (INR) 7.9, fib-
rinogen 4.8 g, and thrombin time 15.7 s. At 15:30, the mass
was detected under ultrasound guiding. The puncture drew
30 mL dark red liquid. Cefoperazone/sulbactam-induced
abnormal coagulation and hematoma were considered. The
drug was withdrawn and vitamin K1 40 mg was given to
correct the coagulation disorder immediately. On July 2,
abdominal pain significantly reduced and the anal exhaust
restored. Blood coagulation function improved visibly (PT
13.4 s, PTT 27.3 s, PT INR 1.2, fibrinogen 5.45 g, and
thrombin time 15.2 s). On July 3, the coagulation function of
the patient returned to normal (PT 11.9 s, PTT 22.9 s, PT
INR 1.06, fibrinogen 5.45 g, and thrombin time 15.7 s). The
symptoms had not recurred; the mass at lower left abdomen
became smaller, which was confirmed by ultrasound
(Fig. 1c). No other treatment was started and stopped at the
same time. The patient was discharged on July 15, at which
time she showed no symptoms.
Discussion
Cefoperazone/sulbactam has good antibacterial effects
against Escherichia coli, Klebsiella, Proteus, Salmonella
typhi, Shigella, other Enterobacteriaceae, and
Pseudomonas aeruginosa. The drug has been used exten-
sively in severe infection of the respiratory system,
digestive system, and genitourinary system. Most of the
patients tolerated it very well. This patient had no history
of abnormal coagulation function and no history of
bleeding, blood system disease, or liver disease. Before
administration of the drug, coagulation function was nor-
mal. No other drug may have affected coagulation function
during this period. After 1 week of cefoperazone/sulbac-
tam, the coagulation index showed abnormality and acti-
vated partial thromboplastin time (APTT) and PT increased
Fig. 1 a Hematoma at lower left abdominal wall was suggested by
abdominal CT. b Mixed masses at left lower abdominal wall was
revealed by the abdomen B ultrasound. c Absorbed hematoma by B
ultrasound
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obviously. Increased APTT might be induced by the defi-
ciency of coagulation factor X, factor V, and prothrombin.
This is commonly caused by liver disease and vitamin K
deficiency. After withdrawal of the drug and administration
of vitamin K1, blood coagulation function was corrected,
and symptoms improved rapidly without recurrence. Other
causes of the bleeding were excluded. Cefoperazone/sul-
bactam was inferred to be a causal factor regarding coag-
ulation dysfunction and hemorrhage because of vitamin K
deficiency.
There have been many reports about cefoperazone-in-
duced hemorrhage and hypoprothrombinemia, especially
before 1990 (Table 1). It seems that hypoprothrombine-
mia was a very common event during therapy. The inci-
dence ranged from 4 to 68 % [15], and the risk was
greatest in debilitated patients with cancer, intra-abdomi-
nal infection, liver disease, and renal failure [2, 13, 15].
Hypoprothrombinemia and bleeding may be caused by
vitamin K deficiency, as suggested by the fact that vita-
min K therapy can resolve both. However, the mechanism
underlying this effect is still unknown. Several mecha-
nisms have been proposed, including eradication of gas-
trointestinal bacteria, direct inhibition of vitamin
K-dependent coagulation, and indirect inhibition of
coagulation [16]. The very high frequency of hypopro-
thrombinemia associated with cefoperazone in the 1990s
also raised a hypothesis about the role of their
N-methylthiotetrazole (NMTT) side chains. NMTT inhi-
bits vitamin K-dependent carboxylation in vitro. Cefop-
erazone has an NMTT side chain at the 3 position of the
cephalosporin nucleus and so might cause hypopro-
thrombinemic bleeding and disulfiram-like reactions.
Vitamin K therapy is routinely given alongside cef-
operazone in some hospitals. However, there is some
question as to whether prophylactic vitamin K is neces-
sary. If it is true that NMTT-containing antibiotics, such
as cefoperazone, can induce hypoprothrombinemia, sup-
plemental vitamin K may be necessary during therapy.
However, some evidence suggests that this hypothesis
may be incorrect. (1) Although NMTT inhibits vitamin
K-dependent carboxylation in vitro, other cephalosporins
without NMTT also induce bleeding. (2) It is not clear
whether antibiotics that contain NMTT liberate sufficient
amounts of NMTT in vivo to antagonize clotting in
patients [16]. (3) Trials in healthy volunteers did not
demonstrate the effect [17]. (4) Normal volunteers
showed in vivo NMTT production, but the order of
magnitude (cefoperazone, moxalactam, and cefotetan in
descending order) was different from the usual order of
clinical risk. There was no NMTT-concentration-versus-
effect relationship. Patients who were vitamin K deficient
were more sensitive to lower NMTT concentrations than
those with normal vitamin K status. In surveillance
studies, NMTT-containing antibiotics were no more fre-
quently associated with hypoprothrombinemia or bleeding
than antibiotics lacking NMTT [18]. (5) Cefoperazone
caused endogenous vitamin K1 2,3-epoxide in 4/5
patients, but these patients showed a statistically signifi-
cant increase in endogenous plasma vitamin K levels [19].
(6) Serum concentrations were not found to be correlated
with hypoprothrombinemia [20]. (7) Several clinical trials
have demonstrated that NMTT antibiotics are not asso-
ciated with hypoprothrombinemia. In one retrospective
cohort study, 374 patients received cefoperazone from
February 1983 to March 1986 at a teaching hospital. This
work concluded that prophylactic vitamin K is probably
not warranted [14]. In another retrospective study, 50
patients underwent urologic procedures and received
cefoperazone for 3 days to prevent infection. This work
also concluded that routine use of vitamin K with cef-
operazone for perioperative prophylaxis of infection may
not be warranted [21]. A prospective, randomized trial of
195 febrile episode in granulocytopenic patients also
concluded that the use of cefoperazone was not associated
with an increased incidence of hypoprothrombinemia
[22]. This evidence further suggests that there is no cor-
relation between NMTT-containing antibiotics and
hypoprothrombinemia.
This report describes the first case of bleeding in our
ward, though cefoperazone/sulbactam is used there very
frequently for severe pulmonary infection and vitamin K is
not prescribed. Published reports strongly suggest that in
the early stage, cefoperazone and cefoperazone/sulbactam
had induced hypoprothrombinemia and bleeding quite
often and severely, but this response has been reported very
rarely since the 1990s (Table 1). The newest clinical trial,
published in 2013, revealed no bleeding in 141 patients
who were not given prophylactic vitamin K, although there
were no data regarding PT [7]. One possible explanation
for this phenomenon is the impurity of the products;
although, this is entirely speculative, as our institution has
continued to obtain the same formulation of cefopera-
zone/sulbactam from the same manufacturer, and there is
no evidence to suggest a change in quality. High-quality
products may lead to fewer and less severe side effects,
including bleeding and hypoprothrombinemia. The real
element responsible for the bleeding and hypoprothrom-
binemia may be not the cefoperazone itself but some other
component in the product. This component may promote
aberrant coagulation and so induce bleeding. There is no
doubt that individual constitution is a key to the side effect,
the same as allergic reactions. The failure of liver and renal
function, advanced age, and malnutrition may be risk fac-
tors but there has been no exclusive evidence until now
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[14]. The dosage and duration may not be associated with
this side effect also [23].
Conclusion
This patient was misdiagnosed with incarceration of the
abdominal hernia because the symptoms were quite similar
to those of hernia. Unfortunately, it caused the clinicians to
overlook the side effects of cefoperazone. Although no
serious consequences were observed in this case, the
warning it offers should be taken seriously. Cefoperazone-
related products can indeed cause vitamin K-dependent
thrombin factor deficiency and hemorrhage, although the
underlying mechanism is still not clear and the incidence is
very low. Once abdominal pain, diarrhea, blood in the
urine, hemoptysis, skin and mucosa petechia or ecchymo-
sis, or hematoma appear, cefoperazone should be consid-
ered. Drug treatment should be stopped immediately, blood
coagulation function should be checked, and supplemental
vitamin K should be considered. This may prevent bleeding
in high-risk patients.
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Table 1 Summary of cefoperazone or cefoperazone/sulbactam associated PT prolongation and bleeding from PubMed
Author Year Drug Case No. PT: No. bleeding Original disease
Bailey et al. [2] 1981 C 62 4 0 Renal failure
Cristiano [13] 1984 C 1 1 0 Acute renal failure
Cohen et al. [1] 1984 C 659 26 0 Clinical trial
Shimada et al. [24] 1984 C 1 1 0 Biliary tract infection
Alitalo et al. [12] 1985 C 3 3 3 One renal failure
Weitekamp et al. [25] 1985 C 4 0 0 Normal
Shenkenberg et al. [26] 1985 C 1 1 1 Renal failure
Andrassy et al. [8] 1986 C 21 1 1 Renal failure
Freedy et al. [27] 1986 C 3 3 3 Cancer or bacteremia
Jones et al. [28] 1986 C 41 10 3 Cancer
Sattler et al. [20] 1986 C 28 18 3 Impaired renal function
Strom et al. [14] 1983–1986 C 374 45/366 183/372 Multiple
Guyot et al. [29] 1987 C 30 1 1 Biliary operation
Greenberg et al. [4] 1987 C/S 70 2 1 Urinary tract infection
Muller et al. [30] 1987 C 39 5 3 Biliary tract infection
Mueller et al. [23] 1987 C 32 14 7 Unspecific
Mangi et al. [31] 1988 C 68 12 0 HAP
Mortimer et al. [32] 1988 C 88 0 0 Febrile neutropenic
Royer et al. [33] 1988 C 2 2 0 Acute renal insufficiency
Jones et al. [34] 1988 C ? K 53 15 3 Cancer
Pegram et al. [22] 1989 C 130 6 3 Febrile granulocytopenic
Scha¨fer et al. [19] 1989 C 5 2 0 Urinary tract infection
Winston et al. [35] 1991 C ? K 138 0 0 Febrile, granulocytopenic
Rockoff et al. [21] 1992 C 50 0 0 Prophylactic use 3d
Li et al. [6] 1993–1994 C/S 103 0 0 Respiratory and urinary infection
Narumi et al. [36] 1998 C 2 2 2 TB ? bile duct cancer
Alagozlu et al. [11] 2006 C 1 1 0 Choledocholithiasis
Wong et al. [37] 2006 C/S 1 1 1 Urinary tract infection
Ozen et al. [38] 2008 C 1 1 1 Meckel’s diverticulum
Xin et al. [7] 2005–2009 C/S 141 0 0 Respiratory and urinary infection
C cefoperazone, C ? K cefoperazone ? vitamin K, C/S cefoperazone/sulbactam, HAP hospital acquired pneumonia, PT prothrombin time, TB
tuberculosis, 3d three days
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Consent Written informed consent was obtained from the patient
for publication of this case report and the accompanying images. A
copy of the written consent may be requested for review from the
corresponding author.
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